carlisle medical
Refill Requests shipment tracking contact carlisle medical
Knowledge Center
generic drug updates
Launch of Generic Butrans
Released: 05/31/2017
By: Heidi Dufrene, PharmD

The FDA has recently approved the generic equivalent of Butrans (Buprenorphine) transdermal patches. Butrans is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Butrans should be reserved for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Butrans is not indicated as an as-needed analgesic.[i] The generic formulation will be available in 5mg, 10mg, 15mg and 20mg. Butrans is also available in a 7.5mg strength that is not included in the current generic release at this time.

Generic prescription drugs approved by the FDA have the same high quality and strength as brand name drugs. Generic prescription drug manufacturing and packaging sites must pass the same quality standards as those of brand name drugs.

If you have any questions or if we may assist you with your pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.

_____________________

[1] 1. Butrans (buprenorphine) [prescribing information]. Stamford, CT: Purdue Pharma; December 2016.

<<Back
 
Company News
Generic Releases
Industry Related News
Industry Related Links
Newsletter Subscription
Newsletter Login
 
 
 
 
 
© Copyright 2017 Carlisle & Medical, Inc.
Twitter Twitter Twitter Twitter
disclaimer site map disclaimer